Table 2 Ongoing clinical trials with spironolactone or finerenone in HFpEF.
Drug | Study Name NCT# | Condition / Disease | Estimated/ Actual Enrollment | Primary endpoint | Study start / completion |
|---|---|---|---|---|---|
Spironolactone | SPIRRIT-HFPEF NCT02901184 | HFmrEF (EF ≥ 40–49%) + HFpEF (EF ≥ 50%) | 2.000 | Time to death from any cause | November 2017/ December 2026 |
Spironolactone | SPIRIT-HF NCT04727073 | HFmrEF (EF ≥ 40–49%) + HFpEF (EF ≥ 50%) | 1.300 | Cumulative number of primary composite events of CV death and total HF hospitalization | November 2018/ December 2024 |
Finerenone | FINEARTS-HF NCT04435626 | HFmrEF (EF ≥ 40–49%) + HFpEF (EF ≥ 50%) | 6.016 | Number of cardiovascular death and heart failure events | September 2020/ August 2024 |